Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyIdentification
- Name
- Ketoprofen
- Accession Number
- DB01009 (APRD01059, DB05823, DB05335)
- Type
- Small Molecule
- Groups
- Approved, Vet approved
- Description
Ketoprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties.
- Structure
Structure for DB01009 (Ketoprofen)
- Synonyms
- 2-(3-Benzoylphenyl)propionic acid
- 3-Benzoyl-alpha-methylbenzeneacetic acid
- 3-Benzoyl-α-methylbenzeneacetic acid
- 3-Benzoylhydratropic acid
- Ketoprofen
- L'Acide (benzoyl-3-phenyl)-2-propionique
- m-Benzoylhydratropic acid
- Orudis (tn)
- Product Ingredients
Ingredient UNII CAS InChI Key Ketoprofen sodium 5R10M39KS7 57495-14-4 OAPDLBHLMVYMCW-UHFFFAOYSA-M - Product Images
- Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Ketoprofen Capsule 50 mg Oral Aa Pharma Inc 1989-12-31 Not applicable Canada 
Ketoprofen SR Tablet, extended release 200 mg Oral Aa Pharma Inc 1995-12-31 Not applicable Canada Ketoprofen Suppositories Suppository 50 mg Rectal Pharmel Inc Not applicable Not applicable Canada Ketoprofen Suppositories Suppository 100 mg Rectal Pharmel Inc 1998-06-04 Not applicable Canada Ketoprofen-E Tablet, delayed release 100 mg Oral Aa Pharma Inc 1989-12-31 Not applicable Canada Ketoprofen-E Tablet, delayed release 50 mg Oral Aa Pharma Inc 1989-12-31 Not applicable Canada Ketoprofen-E Ect 100mg Tablet, delayed release 100 mg Oral Pro Doc Limitee 1996-12-31 2009-07-23 Canada Ketoprofen-E Ect 50mg Tablet, delayed release 50 mg Oral Pro Doc Limitee 1995-12-31 2009-07-23 Canada Ketoprofen-SR - Srt 200mg Tablet, extended release 200 mg Oral Pro Doc Limitee 1997-09-18 2009-07-23 Canada Orafen - Sup RT 100mg Suppository 100 mg Rectal Technilab Pharma Inc. 1996-12-31 2004-08-03 Canada - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Ketoprofen Capsule 75 mg/1 Oral Stat Rx USA 2011-01-18 2018-02-08 US 
Ketoprofen Capsule 75 mg/1 Oral Aidarex Pharmaceuticals LLC 1993-01-01 Not applicable US Ketoprofen Capsule, extended release 200 mg/1 Oral Physicians Total Care, Inc. 2009-06-23 Not applicable US 
Ketoprofen Capsule 50 mg/1 Oral Pd Rx Pharmaceuticals, Inc. 1993-01-01 Not applicable US Ketoprofen Capsule 75 mg/1 Oral Teva 1993-01-01 Not applicable US 
Ketoprofen Capsule 75 mg/1 Oral A S Medication Solutions 1993-01-01 2017-06-20 US 
Ketoprofen Capsule 75 mg/1 Oral Nucare Pharmaceuticals, Inc. 1993-01-01 Not applicable US Ketoprofen Capsule 50 mg/1 Oral A S Medication Solutions 1993-01-01 Not applicable US Ketoprofen Capsule 50 mg/1 Oral Mesource Pharmaceuticals 1993-01-01 Not applicable US Ketoprofen Capsule 75 mg/1 Oral bryant ranch prepack 1993-01-01 Not applicable US - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Ketophene Ketoprofen (33.5 g/33.5g) Kit California Pharmaceuticals, Llc 2016-01-01 Not applicable US Vopac - Ketoprofen, Lidocaine Hydrochloride Pac Ketoprofen Kit Sircle Laboratories, Llc 2015-03-01 2017-07-13 US - International/Other Brands
- Actron / Alrheumun (Teofarma) / Capisten (Kissei) / Epatec (Zeria Shinyaku) / Fastum (Menarini) / Menamin (Daiko Seiyaku) / Orudis (Abbott) / Orudis KT (Sanofi) / Orugesic (Sanofi) / Oruvail (Wyeth) / Oscorel (Sanofi) / Profenid (Sanofi) / Toprec (Sanofi)
- Categories
- Acids, Carbocyclic
- Analgesics
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Anti-Inflammatory Agents, Non-Steroidal (Non-Selective)
- Antiinflammatory and Antirheumatic Products
- Antiinflammatory and Antirheumatic Products, Non-Steroids
- Antiinflammatory Preparations, Non-Steroids for Topical Use
- Central Nervous System Agents
- COX Inhibitors
- COX-1 Inhibitors
- COX-2 Inhibitors
- Cyclooxygenase Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- Enzyme Inhibitors
- Musculo-Skeletal System
- Nephrotoxic agents
- OAT3 Inhibitors
- Other Nonsteroidal Antiimflammatory Agents
- Peripheral Nervous System Agents
- Phenylpropionates
- Propionates
- Sensory System Agents
- Topical Products for Joint and Muscular Pain
- UGT1A1 Substrates
- UNII
- 90Y4QC304K
- CAS number
- 22071-15-4
- Weight
- Average: 254.2806
Monoisotopic: 254.094294314 - Chemical Formula
- C16H14O3
- InChI Key
- DKYWVDODHFEZIM-UHFFFAOYSA-N
- InChI
- InChI=1S/C16H14O3/c1-11(16(18)19)13-8-5-9-14(10-13)15(17)12-6-3-2-4-7-12/h2-11H,1H3,(H,18,19)
- IUPAC Name
- 2-(3-benzoylphenyl)propanoic acid
- SMILES
- CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1
Pharmacology
- Indication
For symptomatic treatment of acute and chronic rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, primary dysmenorrhea and mild to moderate pain associated with musculotendinous trauma (sprains and strains), postoperative (including dental surgery) or postpartum pain.
- Associated Conditions
- Pharmacodynamics
Ketoprofen is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties. Ketoprofen has pharmacologic actions similar to those of other prototypical NSAIDs, which inhibit prostaglandin synthesis. Ketoprofen is used to treat rheumatoid arthritis, osteoarthritis, dysmenorrhea, and alleviate moderate pain.
- Mechanism of action
The anti-inflammatory effects of ketoprofen are believed to be due to inhibition cylooxygenase-2 (COX-2), an enzyme involved in prostaglandin synthesis via the arachidonic acid pathway. This results in decreased levels of prostaglandins that mediate pain, fever and inflammation. Ketoprofen is a non-specific cyclooxygenase inhibitor and inhibition of COX-1 is thought to confer some of its side effects, such as GI upset and ulceration. Ketoprofen is thought to have anti-bradykinin activity, as well as lysosomal membrane-stabilizing action. Antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation.
Target Actions Organism UProstaglandin G/H synthase 1 inhibitorHuman AProstaglandin G/H synthase 2 inhibitorHuman UC-X-C chemokine receptor type 1 otherHuman - Absorption
Ketoprofen is rapidly and well-absorbed orally, with peak plasma levels occurring within 0.5 to 2 hours.
- Volume of distribution
- Not Available
- Protein binding
99% bound, primarily to albumin
- Metabolism
Rapidly and extensively metabolized in the liver, primarily via conjugation to glucuronic acid. No active metabolites have been identified.
- Route of elimination
In a 24 hour period, approximately 80% of an administered dose of ketoprofen is excreted in the urine, primarily as the glucuronide metabolite.
- Half life
Conventional capsules: 1.1-4 hours
Extended release capsules: 5.4 hours due to delayed absorption (intrinsic clearance is same as conventional capsules)
- Clearance
- Oral-dose cl=6.9 +/- 0.8 L/h [Ketoprofen Immediate-release capsules (4 × 50 mg)]
- Oral-dose cl=6.8 +/- 1.8 L/h [Ketoprofen Extended-release capsules (1 × 200 mg)]
- 0.08 L/kg/h
- 0.7 L/kg/h [alcoholic cirrhosis patients]
- Toxicity
LD50=62.4 mg/kg (rat, oral).
Symptoms of overdose include drowsiness, vomiting and abdominal pain.
Side effects are usually mild and mainly involved the GI tract. Most common adverse GI effect is dyspepsia (11% of patients). May cause nausea, diarrhea, abdominal pain, constipation and flatulence in greater than 3% of patients.
- Affected organisms
- Humans and other mammals
- Pathways
Pathway Category Ketoprofen Action Pathway Drug action - Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group (4R)-limonene The risk or severity of adverse effects can be increased when (4R)-limonene is combined with Ketoprofen. Investigational 16-Bromoepiandrosterone The risk or severity of adverse effects can be increased when Ketoprofen is combined with 16-Bromoepiandrosterone. Investigational 19-norandrostenedione The risk or severity of adverse effects can be increased when Ketoprofen is combined with 19-norandrostenedione. Experimental, Illicit 5-androstenedione The risk or severity of adverse effects can be increased when Ketoprofen is combined with 5-androstenedione. Experimental, Illicit Abciximab Ketoprofen may increase the anticoagulant activities of Abciximab. Approved Abiraterone The metabolism of Ketoprofen can be decreased when combined with Abiraterone. Approved Acebutolol Ketoprofen may decrease the antihypertensive activities of Acebutolol. Approved, Investigational Aceclofenac The risk or severity of adverse effects can be increased when Ketoprofen is combined with Aceclofenac. Approved, Investigational Acemetacin The risk or severity of adverse effects can be increased when Ketoprofen is combined with Acemetacin. Approved, Experimental, Investigational Acenocoumarol Ketoprofen may increase the anticoagulant activities of Acenocoumarol. Approved, Investigational Acetyl sulfisoxazole The metabolism of Ketoprofen can be decreased when combined with Acetyl sulfisoxazole. Approved, Vet Approved Adapalene The risk or severity of adverse effects can be increased when Adapalene is combined with Ketoprofen. Approved Alaproclate Alaproclate may increase the antiplatelet activities of Ketoprofen. Experimental Alclofenac The risk or severity of adverse effects can be increased when Alclofenac is combined with Ketoprofen. Approved, Withdrawn Alclometasone The risk or severity of adverse effects can be increased when Ketoprofen is combined with Alclometasone. Approved Aldosterone The risk or severity of adverse effects can be increased when Ketoprofen is combined with Aldosterone. Experimental, Investigational Alendronic acid The risk or severity of adverse effects can be increased when Ketoprofen is combined with Alendronic acid. Approved Aliskiren Ketoprofen may decrease the antihypertensive activities of Aliskiren. Approved, Investigational Alminoprofen The risk or severity of adverse effects can be increased when Alminoprofen is combined with Ketoprofen. Experimental Alprenolol Ketoprofen may decrease the antihypertensive activities of Alprenolol. Approved, Withdrawn Alprostadil The therapeutic efficacy of Alprostadil can be decreased when used in combination with Ketoprofen. Approved, Investigational Amcinonide The risk or severity of adverse effects can be increased when Ketoprofen is combined with Amcinonide. Approved Amikacin The risk or severity of nephrotoxicity can be increased when Ketoprofen is combined with Amikacin. Approved, Investigational, Vet Approved Amiloride Ketoprofen may decrease the antihypertensive activities of Amiloride. Approved Aminosalicylic Acid The risk or severity of adverse effects can be increased when Ketoprofen is combined with Aminosalicylic Acid. Approved Amlodipine The therapeutic efficacy of Amlodipine can be decreased when used in combination with Ketoprofen. Approved Amodiaquine The serum concentration of Amodiaquine can be increased when it is combined with Ketoprofen. Approved, Investigational Ancrod Ketoprofen may increase the anticoagulant activities of Ancrod. Approved, Investigational Andrographolide The risk or severity of adverse effects can be increased when Andrographolide is combined with Ketoprofen. Investigational Androstenedione The risk or severity of adverse effects can be increased when Ketoprofen is combined with Androstenedione. Experimental, Illicit Anecortave The risk or severity of adverse effects can be increased when Ketoprofen is combined with Anecortave. Investigational anecortave acetate The risk or severity of adverse effects can be increased when Ketoprofen is combined with anecortave acetate. Investigational Anisodamine The risk or severity of adverse effects can be increased when Anisodamine is combined with Ketoprofen. Investigational Antipyrine The risk or severity of adverse effects can be increased when Ketoprofen is combined with Antipyrine. Approved, Investigational Antithrombin III human Ketoprofen may increase the anticoagulant activities of Antithrombin III human. Approved Antrafenine The risk or severity of adverse effects can be increased when Ketoprofen is combined with Antrafenine. Approved Apalutamide The serum concentration of Ketoprofen can be decreased when it is combined with Apalutamide. Approved, Investigational Apixaban Ketoprofen may increase the anticoagulant activities of Apixaban. Approved Apocynin The risk or severity of adverse effects can be increased when Apocynin is combined with Ketoprofen. Investigational Apramycin Ketoprofen may decrease the excretion rate of Apramycin which could result in a higher serum level. Experimental, Vet Approved Apremilast The risk or severity of adverse effects can be increased when Apremilast is combined with Ketoprofen. Approved, Investigational Aprepitant The metabolism of Ketoprofen can be increased when combined with Aprepitant. Approved, Investigational Arbekacin Ketoprofen may decrease the excretion rate of Arbekacin which could result in a higher serum level. Approved, Investigational Ardeparin Ketoprofen may increase the anticoagulant activities of Ardeparin. Approved, Investigational, Withdrawn Argatroban Ketoprofen may increase the anticoagulant activities of Argatroban. Approved, Investigational Arotinolol Ketoprofen may decrease the antihypertensive activities of Arotinolol. Investigational Asenapine Ketoprofen may decrease the antihypertensive activities of Asenapine. Approved Atamestane The risk or severity of adverse effects can be increased when Ketoprofen is combined with Atamestane. Investigational Atenolol Ketoprofen may decrease the antihypertensive activities of Atenolol. Approved Azapropazone The risk or severity of adverse effects can be increased when Azapropazone is combined with Ketoprofen. Withdrawn Azelastine The risk or severity of adverse effects can be increased when Azelastine is combined with Ketoprofen. Approved Azficel-T The risk or severity of adverse effects can be increased when Ketoprofen is combined with Azficel-T. Approved, Investigational Azilsartan medoxomil The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Ketoprofen. Approved, Investigational Azosemide The therapeutic efficacy of Azosemide can be decreased when used in combination with Ketoprofen. Investigational Bacitracin The risk or severity of nephrotoxicity can be increased when Ketoprofen is combined with Bacitracin. Approved, Vet Approved Balsalazide The risk or severity of adverse effects can be increased when Ketoprofen is combined with Balsalazide. Approved, Investigational Bazedoxifene Ketoprofen may increase the thrombogenic activities of Bazedoxifene. Approved, Investigational Becaplermin Ketoprofen may increase the anticoagulant activities of Becaplermin. Approved, Investigational Beclomethasone dipropionate The risk or severity of gastrointestinal irritation can be increased when Beclomethasone dipropionate is combined with Ketoprofen. Approved, Investigational Befunolol Ketoprofen may decrease the antihypertensive activities of Befunolol. Experimental Bekanamycin Ketoprofen may decrease the excretion rate of Bekanamycin which could result in a higher serum level. Experimental Benazepril The risk or severity of adverse effects can be increased when Ketoprofen is combined with Benazepril. Approved, Investigational Bendazac The risk or severity of adverse effects can be increased when Bendazac is combined with Ketoprofen. Experimental Bendroflumethiazide The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Ketoprofen. Approved Benorilate The risk or severity of adverse effects can be increased when Benorilate is combined with Ketoprofen. Experimental Benoxaprofen The risk or severity of adverse effects can be increased when Benoxaprofen is combined with Ketoprofen. Withdrawn Benzthiazide The therapeutic efficacy of Benzthiazide can be decreased when used in combination with Ketoprofen. Approved Benzydamine The risk or severity of adverse effects can be increased when Benzydamine is combined with Ketoprofen. Approved Bepridil The therapeutic efficacy of Bepridil can be decreased when used in combination with Ketoprofen. Approved, Withdrawn Beraprost The therapeutic efficacy of Beraprost can be decreased when used in combination with Ketoprofen. Investigational Betamethasone The risk or severity of adverse effects can be increased when Ketoprofen is combined with Betamethasone. Approved, Vet Approved Betaxolol Ketoprofen may decrease the antihypertensive activities of Betaxolol. Approved, Investigational Betrixaban The risk or severity of bleeding can be increased when Betrixaban is combined with Ketoprofen. Approved, Investigational Bevantolol Ketoprofen may decrease the antihypertensive activities of Bevantolol. Approved Bevonium The risk or severity of adverse effects can be increased when Bevonium is combined with Ketoprofen. Experimental Bimatoprost The therapeutic efficacy of Bimatoprost can be decreased when used in combination with Ketoprofen. Approved, Investigational Bisoprolol Ketoprofen may decrease the antihypertensive activities of Bisoprolol. Approved Bivalirudin Ketoprofen may increase the anticoagulant activities of Bivalirudin. Approved, Investigational Bopindolol Ketoprofen may decrease the antihypertensive activities of Bopindolol. Approved Bromfenac The risk or severity of adverse effects can be increased when Bromfenac is combined with Ketoprofen. Approved Bucillamine The risk or severity of adverse effects can be increased when Bucillamine is combined with Ketoprofen. Investigational Bucindolol Ketoprofen may decrease the antihypertensive activities of Bucindolol. Investigational Budesonide The risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Ketoprofen. Approved Bufexamac The risk or severity of adverse effects can be increased when Ketoprofen is combined with Bufexamac. Approved, Experimental Bufuralol Ketoprofen may decrease the antihypertensive activities of Bufuralol. Experimental, Investigational Bumadizone The risk or severity of adverse effects can be increased when Bumadizone is combined with Ketoprofen. Experimental Bumetanide The therapeutic efficacy of Bumetanide can be decreased when used in combination with Ketoprofen. Approved Bupranolol Ketoprofen may decrease the antihypertensive activities of Bupranolol. Approved Candesartan The risk or severity of adverse effects can be increased when Candesartan is combined with Ketoprofen. Experimental Candesartan cilexetil The risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Ketoprofen. Approved Candoxatril The risk or severity of adverse effects can be increased when Ketoprofen is combined with Candoxatril. Experimental Capecitabine The metabolism of Ketoprofen can be decreased when combined with Capecitabine. Approved, Investigational Capsaicin The risk or severity of adverse effects can be increased when Ketoprofen is combined with Capsaicin. Approved Captopril The risk or severity of adverse effects can be increased when Ketoprofen is combined with Captopril. Approved Carbamazepine The serum concentration of Ketoprofen can be decreased when it is combined with Carbamazepine. Approved, Investigational Carbaspirin calcium The risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Ketoprofen. Experimental, Investigational Carboprost Tromethamine The therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Ketoprofen. Approved Carprofen The risk or severity of adverse effects can be increased when Carprofen is combined with Ketoprofen. Approved, Vet Approved, Withdrawn Carteolol Ketoprofen may decrease the antihypertensive activities of Carteolol. Approved Carvedilol Ketoprofen may decrease the antihypertensive activities of Carvedilol. Approved, Investigational Castanospermine The risk or severity of adverse effects can be increased when Castanospermine is combined with Ketoprofen. Experimental Celecoxib The risk or severity of adverse effects can be increased when Celecoxib is combined with Ketoprofen. Approved, Investigational Celiprolol Ketoprofen may decrease the antihypertensive activities of Celiprolol. Approved, Investigational Ceritinib The serum concentration of Ketoprofen can be increased when it is combined with Ceritinib. Approved Certoparin Ketoprofen may increase the anticoagulant activities of Certoparin. Approved, Investigational Chloroquine The risk or severity of adverse effects can be increased when Chloroquine is combined with Ketoprofen. Approved, Investigational, Vet Approved Chlorothiazide The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Ketoprofen. Approved, Vet Approved Chlorotrianisene Ketoprofen may increase the thrombogenic activities of Chlorotrianisene. Investigational, Withdrawn Chlorphenesin The risk or severity of adverse effects can be increased when Ketoprofen is combined with Chlorphenesin. Approved, Vet Approved, Withdrawn Chlorthalidone The therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Ketoprofen. Approved Cholecalciferol The metabolism of Ketoprofen can be decreased when combined with Cholecalciferol. Approved, Nutraceutical Cholestyramine Cholestyramine can cause a decrease in the absorption of Ketoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Choline magnesium trisalicylate The risk or severity of adverse effects can be increased when Ketoprofen is combined with Choline magnesium trisalicylate. Approved Ciclesonide The risk or severity of adverse effects can be increased when Ketoprofen is combined with Ciclesonide. Approved, Investigational Cilazapril The risk or severity of adverse effects can be increased when Ketoprofen is combined with Cilazapril. Approved Cimicoxib The risk or severity of adverse effects can be increased when Ketoprofen is combined with Cimicoxib. Investigational Cinoxacin Ketoprofen may increase the neuroexcitatory activities of Cinoxacin. Approved, Investigational, Withdrawn Ciprofloxacin Ketoprofen may increase the neuroexcitatory activities of Ciprofloxacin. Approved, Investigational Cisplatin The risk or severity of adverse effects can be increased when Ketoprofen is combined with Cisplatin. Approved Citalopram Citalopram may increase the antiplatelet activities of Ketoprofen. Approved Clobetasol The risk or severity of adverse effects can be increased when Ketoprofen is combined with Clobetasol. Approved, Investigational Clobetasol propionate The risk or severity of adverse effects can be increased when Ketoprofen is combined with Clobetasol propionate. Approved Clobetasone The risk or severity of adverse effects can be increased when Ketoprofen is combined with Clobetasone. Approved Clocortolone The risk or severity of adverse effects can be increased when Ketoprofen is combined with Clocortolone. Approved Clodronic Acid The risk or severity of adverse effects can be increased when Ketoprofen is combined with Clodronic Acid. Approved, Investigational, Vet Approved Clonixin The risk or severity of adverse effects can be increased when Clonixin is combined with Ketoprofen. Approved Cloprostenol The therapeutic efficacy of Cloprostenol can be decreased when used in combination with Ketoprofen. Vet Approved Cloranolol Ketoprofen may decrease the antihypertensive activities of Cloranolol. Experimental Clorindione Ketoprofen may increase the anticoagulant activities of Clorindione. Experimental Colesevelam Colesevelam can cause a decrease in the absorption of Ketoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Colestipol Colestipol can cause a decrease in the absorption of Ketoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Conjugated estrogens Ketoprofen may increase the thrombogenic activities of Conjugated estrogens. Approved Cortexolone 17α-propionate The risk or severity of adverse effects can be increased when Ketoprofen is combined with Cortexolone 17α-propionate. Investigational Corticosterone The risk or severity of adverse effects can be increased when Ketoprofen is combined with Corticosterone. Experimental Cortisone acetate The risk or severity of adverse effects can be increased when Ketoprofen is combined with Cortisone acetate. Approved, Investigational Crisaborole The metabolism of Ketoprofen can be decreased when combined with Crisaborole. Approved, Investigational Curcumin The risk or severity of adverse effects can be increased when Curcumin is combined with Ketoprofen. Approved, Investigational Cyclopenthiazide The therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Ketoprofen. Experimental Cyclosporine The risk or severity of renal failure and hypertension can be increased when Ketoprofen is combined with Cyclosporine. Approved, Investigational, Vet Approved Dabigatran etexilate Ketoprofen may increase the anticoagulant activities of Dabigatran etexilate. Approved Dabrafenib The serum concentration of Ketoprofen can be decreased when it is combined with Dabrafenib. Approved, Investigational Daidzein Ketoprofen may increase the thrombogenic activities of Daidzein. Experimental Dalteparin Ketoprofen may increase the anticoagulant activities of Dalteparin. Approved Danaparoid Ketoprofen may increase the anticoagulant activities of Danaparoid. Approved, Withdrawn Dapoxetine Dapoxetine may increase the antiplatelet activities of Ketoprofen. Investigational Darexaban Ketoprofen may increase the anticoagulant activities of Darexaban. Investigational Deferasirox The risk or severity of adverse effects can be increased when Ketoprofen is combined with Deferasirox. Approved, Investigational Deflazacort The risk or severity of adverse effects can be increased when Ketoprofen is combined with Deflazacort. Approved, Investigational Delapril The risk or severity of adverse effects can be increased when Ketoprofen is combined with Delapril. Investigational Delavirdine The metabolism of Ketoprofen can be decreased when combined with Delavirdine. Approved Desipramine Ketoprofen may decrease the antihypertensive activities of Desipramine. Approved, Investigational Desirudin Ketoprofen may increase the anticoagulant activities of Desirudin. Approved Desmopressin The risk or severity of adverse effects can be increased when Ketoprofen is combined with Desmopressin. Approved Desonide The risk or severity of adverse effects can be increased when Ketoprofen is combined with Desonide. Approved, Investigational Desoximetasone The risk or severity of adverse effects can be increased when Ketoprofen is combined with Desoximetasone. Approved Desoxycorticosterone acetate The risk or severity of adverse effects can be increased when Ketoprofen is combined with Desoxycorticosterone acetate. Approved Desoxycorticosterone Pivalate The risk or severity of adverse effects can be increased when Ketoprofen is combined with Desoxycorticosterone Pivalate. Experimental, Vet Approved Desvenlafaxine Desvenlafaxine may increase the antiplatelet activities of Ketoprofen. Approved, Investigational Dexamethasone The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Ketoprofen. Approved, Investigational, Vet Approved Dexamethasone isonicotinate The risk or severity of adverse effects can be increased when Ketoprofen is combined with Dexamethasone isonicotinate. Vet Approved Dexibuprofen The risk or severity of adverse effects can be increased when Ketoprofen is combined with Dexibuprofen. Approved, Investigational Dexketoprofen The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Ketoprofen. Approved, Investigational Dexniguldipine The therapeutic efficacy of Dexniguldipine can be decreased when used in combination with Ketoprofen. Experimental Dextran Ketoprofen may increase the anticoagulant activities of Dextran. Approved, Investigational, Vet Approved Dibekacin Ketoprofen may decrease the excretion rate of Dibekacin which could result in a higher serum level. Experimental Dibotermin alfa The risk or severity of adverse effects can be increased when Ketoprofen is combined with Dibotermin alfa. Approved, Investigational Diclofenac The risk or severity of adverse effects can be increased when Diclofenac is combined with Ketoprofen. Approved, Vet Approved Dicoumarol Ketoprofen may increase the anticoagulant activities of Dicoumarol. Approved Dienestrol Ketoprofen may increase the thrombogenic activities of Dienestrol. Approved, Investigational Diethylstilbestrol Ketoprofen may increase the thrombogenic activities of Diethylstilbestrol. Approved, Investigational Difenpiramide The risk or severity of adverse effects can be increased when Difenpiramide is combined with Ketoprofen. Experimental Diflorasone The risk or severity of adverse effects can be increased when Ketoprofen is combined with Diflorasone. Approved Diflunisal The risk or severity of adverse effects can be increased when Diflunisal is combined with Ketoprofen. Approved, Investigational Difluocortolone The risk or severity of adverse effects can be increased when Ketoprofen is combined with Difluocortolone. Approved, Investigational, Withdrawn Difluprednate The risk or severity of adverse effects can be increased when Ketoprofen is combined with Difluprednate. Approved Digoxin The serum concentration of Digoxin can be increased when it is combined with Ketoprofen. Approved Dihydrostreptomycin Ketoprofen may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level. Investigational, Vet Approved Diltiazem The therapeutic efficacy of Diltiazem can be decreased when used in combination with Ketoprofen. Approved, Investigational Dinoprost The therapeutic efficacy of Dinoprost can be decreased when used in combination with Ketoprofen. Investigational Dinoprost Tromethamine The therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Ketoprofen. Approved, Vet Approved Dinoprostone The therapeutic efficacy of Dinoprostone can be decreased when used in combination with Ketoprofen. Approved Diphenadione Ketoprofen may increase the anticoagulant activities of Diphenadione. Experimental Dosulepin The metabolism of Ketoprofen can be decreased when combined with Dosulepin. Approved Doxazosin The therapeutic efficacy of Doxazosin can be decreased when used in combination with Ketoprofen. Approved Drospirenone Ketoprofen may increase the hyperkalemic activities of Drospirenone. Approved Droxicam The risk or severity of adverse effects can be increased when Ketoprofen is combined with Droxicam. Withdrawn Duloxetine Duloxetine may increase the antiplatelet activities of Ketoprofen. Approved Duvelisib The risk or severity of adverse effects can be increased when Duvelisib is combined with Ketoprofen. Investigational E-6201 The risk or severity of adverse effects can be increased when E-6201 is combined with Ketoprofen. Investigational Edetic Acid Ketoprofen may increase the anticoagulant activities of Edetic Acid. Approved, Vet Approved Edoxaban Ketoprofen may increase the anticoagulant activities of Edoxaban. Approved Efavirenz The metabolism of Ketoprofen can be decreased when combined with Efavirenz. Approved, Investigational Efonidipine The therapeutic efficacy of Efonidipine can be decreased when used in combination with Ketoprofen. Approved, Investigational Enalapril The risk or severity of adverse effects can be increased when Ketoprofen is combined with Enalapril. Approved, Vet Approved Enalaprilat The risk or severity of adverse effects can be increased when Ketoprofen is combined with Enalaprilat. Approved Enoxacin Ketoprofen may increase the neuroexcitatory activities of Enoxacin. Approved, Investigational Enoxaparin Ketoprofen may increase the anticoagulant activities of Enoxaparin. Approved Enprostil The therapeutic efficacy of Enprostil can be decreased when used in combination with Ketoprofen. Experimental Epanolol Ketoprofen may decrease the antihypertensive activities of Epanolol. Experimental Epimestrol Ketoprofen may increase the thrombogenic activities of Epimestrol. Experimental Epirizole The risk or severity of adverse effects can be increased when Epirizole is combined with Ketoprofen. Approved Epitizide The therapeutic efficacy of Epitizide can be decreased when used in combination with Ketoprofen. Experimental Eplerenone Ketoprofen may decrease the antihypertensive activities of Eplerenone. Approved Epoprostenol The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Ketoprofen. Approved Eprosartan The risk or severity of adverse effects can be increased when Eprosartan is combined with Ketoprofen. Approved Equilenin The risk or severity of adverse effects can be increased when Ketoprofen is combined with Equilenin. Experimental Equilin The risk or severity of adverse effects can be increased when Ketoprofen is combined with Equilin. Approved Equol Ketoprofen may increase the thrombogenic activities of Equol. Investigational Esatenolol Ketoprofen may decrease the antihypertensive activities of Esatenolol. Experimental Escitalopram Escitalopram may increase the antiplatelet activities of Ketoprofen. Approved, Investigational Esmolol Ketoprofen may decrease the antihypertensive activities of Esmolol. Approved Estradiol The excretion of Estradiol can be decreased when combined with Ketoprofen. Approved, Investigational, Vet Approved Estradiol acetate Ketoprofen may increase the thrombogenic activities of Estradiol acetate. Approved, Investigational, Vet Approved Estradiol cypionate Ketoprofen may increase the thrombogenic activities of Estradiol cypionate. Approved, Investigational, Vet Approved Estradiol valerate Ketoprofen may increase the thrombogenic activities of Estradiol valerate. Approved, Investigational, Vet Approved Estriol Ketoprofen may increase the thrombogenic activities of Estriol. Approved, Investigational, Vet Approved Estrogens, esterified Ketoprofen may increase the thrombogenic activities of Estrogens, esterified. Approved Estrone The risk or severity of adverse effects can be increased when Ketoprofen is combined with Estrone. Approved Estrone sulfate The risk or severity of adverse effects can be increased when Ketoprofen is combined with Estrone sulfate. Approved Etacrynic acid The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Ketoprofen. Approved, Investigational Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Ketoprofen. Approved, Investigational Ethenzamide The risk or severity of adverse effects can be increased when Ethenzamide is combined with Ketoprofen. Experimental Ethinyl Estradiol The serum concentration of Ketoprofen can be decreased when it is combined with Ethinyl Estradiol. Approved Ethyl biscoumacetate Ketoprofen may increase the anticoagulant activities of Ethyl biscoumacetate. Withdrawn Etidronic acid The risk or severity of adverse effects can be increased when Ketoprofen is combined with Etidronic acid. Approved Etodolac The risk or severity of adverse effects can be increased when Etodolac is combined with Ketoprofen. Approved, Investigational, Vet Approved Etofenamate The risk or severity of adverse effects can be increased when Etofenamate is combined with Ketoprofen. Approved, Investigational Etoperidone Etoperidone may increase the antiplatelet activities of Ketoprofen. Withdrawn Etoricoxib The risk or severity of adverse effects can be increased when Ketoprofen is combined with Etoricoxib. Approved, Investigational Etravirine The metabolism of Ketoprofen can be decreased when combined with Etravirine. Approved Evening primrose oil The risk or severity of adverse effects can be increased when Evening primrose oil is combined with Ketoprofen. Investigational, Nutraceutical Exisulind The risk or severity of adverse effects can be increased when Exisulind is combined with Ketoprofen. Investigational Felbinac The risk or severity of adverse effects can be increased when Felbinac is combined with Ketoprofen. Experimental Felodipine The therapeutic efficacy of Felodipine can be decreased when used in combination with Ketoprofen. Approved, Investigational Fenbufen The risk or severity of adverse effects can be increased when Fenbufen is combined with Ketoprofen. Approved Fenoprofen The risk or severity of adverse effects can be increased when Fenoprofen is combined with Ketoprofen. Approved Fenprostalene The therapeutic efficacy of Fenprostalene can be decreased when used in combination with Ketoprofen. Vet Approved Fentiazac The risk or severity of adverse effects can be increased when Fentiazac is combined with Ketoprofen. Experimental Feprazone The risk or severity of adverse effects can be increased when Feprazone is combined with Ketoprofen. Experimental Ferulic acid The risk or severity of adverse effects can be increased when Ferulic acid is combined with Ketoprofen. Experimental Fimasartan The risk or severity of adverse effects can be increased when Fimasartan is combined with Ketoprofen. Approved, Investigational Fleroxacin Ketoprofen may increase the neuroexcitatory activities of Fleroxacin. Approved Floctafenine The risk or severity of adverse effects can be increased when Floctafenine is combined with Ketoprofen. Approved, Withdrawn Floxuridine The metabolism of Ketoprofen can be decreased when combined with Floxuridine. Approved Fluasterone The risk or severity of adverse effects can be increased when Ketoprofen is combined with Fluasterone. Investigational Fluconazole The metabolism of Ketoprofen can be decreased when combined with Fluconazole. Approved, Investigational Fludrocortisone The risk or severity of adverse effects can be increased when Ketoprofen is combined with Fludrocortisone. Approved, Investigational Fluindione Ketoprofen may increase the anticoagulant activities of Fluindione. Approved, Investigational Flumequine Ketoprofen may increase the neuroexcitatory activities of Flumequine. Withdrawn Flumethasone The risk or severity of adverse effects can be increased when Ketoprofen is combined with Flumethasone. Approved, Vet Approved Flunisolide The risk or severity of adverse effects can be increased when Ketoprofen is combined with Flunisolide. Approved, Investigational Flunixin The risk or severity of adverse effects can be increased when Flunixin is combined with Ketoprofen. Vet Approved Flunoxaprofen The risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Ketoprofen. Experimental Fluocinolone Acetonide The risk or severity of adverse effects can be increased when Ketoprofen is combined with Fluocinolone Acetonide. Approved, Investigational, Vet Approved Fluocinonide The risk or severity of adverse effects can be increased when Ketoprofen is combined with Fluocinonide. Approved, Investigational Fluocortolone The risk or severity of adverse effects can be increased when Ketoprofen is combined with Fluocortolone. Approved, Withdrawn Fluorometholone The risk or severity of adverse effects can be increased when Ketoprofen is combined with Fluorometholone. Approved, Investigational Fluorouracil The metabolism of Ketoprofen can be decreased when combined with Fluorouracil. Approved Fluoxetine Fluoxetine may increase the antiplatelet activities of Ketoprofen. Approved, Vet Approved Fluprednidene The risk or severity of adverse effects can be increased when Ketoprofen is combined with Fluprednidene. Approved, Withdrawn Fluprednisolone The risk or severity of adverse effects can be increased when Ketoprofen is combined with Fluprednisolone. Approved Fluprostenol The therapeutic efficacy of Fluprostenol can be decreased when used in combination with Ketoprofen. Vet Approved Flurandrenolide The risk or severity of adverse effects can be increased when Ketoprofen is combined with Flurandrenolide. Approved Flurbiprofen The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Ketoprofen. Approved, Investigational Fluticasone The risk or severity of adverse effects can be increased when Ketoprofen is combined with Fluticasone. Approved, Experimental, Investigational Fluticasone furoate The risk or severity of adverse effects can be increased when Ketoprofen is combined with Fluticasone furoate. Approved Fluticasone propionate The risk or severity of gastrointestinal irritation can be increased when Fluticasone propionate is combined with Ketoprofen. Approved Fluvoxamine Fluvoxamine may increase the antiplatelet activities of Ketoprofen. Approved, Investigational Folic Acid The therapeutic efficacy of Folic Acid can be decreased when used in combination with Ketoprofen. Approved, Nutraceutical, Vet Approved Fondaparinux Ketoprofen may increase the anticoagulant activities of Fondaparinux sodium. Approved, Investigational Forasartan The risk or severity of adverse effects can be increased when Forasartan is combined with Ketoprofen. Experimental Formestane The risk or severity of adverse effects can be increased when Ketoprofen is combined with Formestane. Approved, Investigational, Withdrawn Fosinopril The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ketoprofen is combined with Fosinopril. Approved Fosphenytoin The metabolism of Ketoprofen can be increased when combined with Fosphenytoin. Approved, Investigational Framycetin Ketoprofen may decrease the excretion rate of Framycetin which could result in a higher serum level. Approved Furosemide The therapeutic efficacy of Furosemide can be decreased when used in combination with Ketoprofen. Approved, Vet Approved Gabexate Ketoprofen may increase the anticoagulant activities of Gabexate. Investigational Garenoxacin Ketoprofen may increase the neuroexcitatory activities of Garenoxacin. Investigational Gatifloxacin Ketoprofen may increase the neuroexcitatory activities of Gatifloxacin. Approved, Investigational Gemeprost The therapeutic efficacy of Gemeprost can be decreased when used in combination with Ketoprofen. Approved, Withdrawn Gemfibrozil The metabolism of Ketoprofen can be decreased when combined with Gemfibrozil. Approved Gemifloxacin Ketoprofen may increase the neuroexcitatory activities of Gemifloxacin. Approved, Investigational Geneticin Ketoprofen may decrease the excretion rate of Geneticin which could result in a higher serum level. Experimental Genistein Ketoprofen may increase the thrombogenic activities of Genistein. Investigational Gentamicin Ketoprofen may decrease the excretion rate of Gentamicin which could result in a higher serum level. Approved, Vet Approved GENTAMICIN C1A Ketoprofen may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level. Experimental Ginseng The risk or severity of adverse effects can be increased when Ketoprofen is combined with Ginseng. Approved, Investigational, Nutraceutical Glipizide The protein binding of Glipizide can be decreased when combined with Ketoprofen. Approved, Investigational Glyburide The protein binding of Glyburide can be decreased when combined with Ketoprofen. Approved Grepafloxacin Ketoprofen may increase the neuroexcitatory activities of Grepafloxacin. Approved, Investigational, Withdrawn Guacetisal The risk or severity of adverse effects can be increased when Guacetisal is combined with Ketoprofen. Experimental Guanfacine The therapeutic efficacy of Guanfacine can be decreased when used in combination with Ketoprofen. Approved, Investigational Halcinonide The risk or severity of adverse effects can be increased when Ketoprofen is combined with Halcinonide. Approved, Investigational, Withdrawn Haloperidol The risk or severity of adverse effects can be increased when Ketoprofen is combined with Haloperidol. Approved HE3286 The risk or severity of adverse effects can be increased when Ketoprofen is combined with HE3286. Investigational Heparin Ketoprofen may increase the anticoagulant activities of Heparin. Approved, Investigational Hexestrol Ketoprofen may increase the thrombogenic activities of Hexestrol. Withdrawn Higenamine The risk or severity of adverse effects can be increased when Higenamine is combined with Ketoprofen. Investigational Hydralazine Ketoprofen may decrease the antihypertensive activities of Hydralazine. Approved Hydrochlorothiazide The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Ketoprofen. Approved, Vet Approved Hydrocortisone The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Ketoprofen. Approved, Vet Approved Hydrocortisone acetate The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone acetate is combined with Ketoprofen. Approved, Vet Approved Hydrocortisone butyrate The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone butyrate is combined with Ketoprofen. Approved, Vet Approved Hydroflumethiazide The therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Ketoprofen. Approved, Investigational Hygromycin B Ketoprofen may decrease the excretion rate of Hygromycin B which could result in a higher serum level. Vet Approved Ibandronate The risk or severity of gastrointestinal bleeding can be increased when Ketoprofen is combined with Ibandronate. Approved, Investigational Ibuprofen The risk or severity of adverse effects can be increased when Ketoprofen is combined with Ibuprofen. Approved Ibuproxam The risk or severity of adverse effects can be increased when Ibuproxam is combined with Ketoprofen. Withdrawn Icatibant The risk or severity of adverse effects can be increased when Icatibant is combined with Ketoprofen. Approved, Investigational Icosapent The risk or severity of adverse effects can be increased when Ketoprofen is combined with Icosapent. Approved, Nutraceutical Idraparinux Ketoprofen may increase the anticoagulant activities of Idraparinux. Investigational Iloprost The therapeutic efficacy of Iloprost can be decreased when used in combination with Ketoprofen. Approved, Investigational Imidapril The risk or severity of adverse effects can be increased when Ketoprofen is combined with Imidapril. Investigational Imidazole salicylate The risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Ketoprofen. Experimental Indalpine Indalpine may increase the antiplatelet activities of Ketoprofen. Investigational, Withdrawn Indapamide The therapeutic efficacy of Indapamide can be decreased when used in combination with Ketoprofen. Approved Indenolol Ketoprofen may decrease the antihypertensive activities of Indenolol. Withdrawn Indinavir The metabolism of Ketoprofen can be decreased when combined with Indinavir. Approved Indobufen The risk or severity of adverse effects can be increased when Indobufen is combined with Ketoprofen. Investigational Indomethacin The risk or severity of adverse effects can be increased when Indomethacin is combined with Ketoprofen. Approved, Investigational Indoprofen The risk or severity of adverse effects can be increased when Indoprofen is combined with Ketoprofen. Withdrawn Irbesartan The metabolism of Ketoprofen can be decreased when combined with Irbesartan. Approved, Investigational Isepamicin Ketoprofen may decrease the excretion rate of Isepamicin which could result in a higher serum level. Experimental Isoxicam The risk or severity of adverse effects can be increased when Isoxicam is combined with Ketoprofen. Withdrawn Isradipine The therapeutic efficacy of Isradipine can be decreased when used in combination with Ketoprofen. Approved, Investigational Istaroxime The risk or severity of adverse effects can be increased when Ketoprofen is combined with Istaroxime. Investigational Kanamycin Ketoprofen may decrease the excretion rate of Kanamycin which could result in a higher serum level. Approved, Investigational, Vet Approved Kebuzone The risk or severity of adverse effects can be increased when Kebuzone is combined with Ketoprofen. Experimental Ketoconazole The metabolism of Ketoprofen can be decreased when combined with Ketoconazole. Approved, Investigational Ketorolac The risk or severity of adverse effects can be increased when Ketorolac is combined with Ketoprofen. Approved Labetalol Ketoprofen may decrease the antihypertensive activities of Labetalol. Approved Lacidipine The therapeutic efficacy of Lacidipine can be decreased when used in combination with Ketoprofen. Approved, Investigational Lamotrigine The serum concentration of Ketoprofen can be decreased when it is combined with Lamotrigine. Approved, Investigational Landiolol Ketoprofen may decrease the antihypertensive activities of Landiolol. Investigational Latanoprost The therapeutic efficacy of Latanoprost can be decreased when used in combination with Ketoprofen. Approved, Investigational Latanoprostene Bunod The therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Ketoprofen. Approved, Investigational Leflunomide The risk or severity of adverse effects can be increased when Leflunomide is combined with Ketoprofen. Approved, Investigational Lepirudin Ketoprofen may increase the anticoagulant activities of Lepirudin. Approved Lercanidipine The therapeutic efficacy of Lercanidipine can be decreased when used in combination with Ketoprofen. Approved, Investigational Letaxaban Ketoprofen may increase the anticoagulant activities of Letaxaban. Investigational Levobetaxolol Ketoprofen may decrease the antihypertensive activities of Levobetaxolol. Approved, Investigational Levobunolol Ketoprofen may decrease the antihypertensive activities of Levobunolol. Approved Levofloxacin Ketoprofen may increase the neuroexcitatory activities of Levofloxacin. Approved, Investigational Levomilnacipran Levomilnacipran may increase the antiplatelet activities of Ketoprofen. Approved, Investigational Limaprost The therapeutic efficacy of Limaprost can be decreased when used in combination with Ketoprofen. Approved, Investigational Lisinopril The risk or severity of adverse effects can be increased when Ketoprofen is combined with Lisinopril. Approved, Investigational Lisofylline The risk or severity of adverse effects can be increased when Lisofylline is combined with Ketoprofen. Investigational Lithium cation The serum concentration of Lithium can be increased when it is combined with Ketoprofen. Experimental Lobeglitazone The metabolism of Ketoprofen can be decreased when combined with Lobeglitazone. Approved, Investigational Lomefloxacin Ketoprofen may increase the neuroexcitatory activities of Lomefloxacin. Approved, Investigational Lonazolac The risk or severity of adverse effects can be increased when Lonazolac is combined with Ketoprofen. Experimental Lornoxicam The risk or severity of adverse effects can be increased when Ketoprofen is combined with Lornoxicam. Approved, Investigational Losartan The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Ketoprofen. Approved Loteprednol The risk or severity of adverse effects can be increased when Ketoprofen is combined with Loteprednol. Approved Lovastatin The metabolism of Ketoprofen can be decreased when combined with Lovastatin. Approved, Investigational Loxoprofen The risk or severity of adverse effects can be increased when Loxoprofen is combined with Ketoprofen. Approved, Investigational Lubiprostone The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Ketoprofen. Approved, Investigational Lumacaftor The serum concentration of Ketoprofen can be decreased when it is combined with Lumacaftor. Approved Lumiracoxib The risk or severity of adverse effects can be increased when Ketoprofen is combined with Lumiracoxib. Approved, Investigational Luprostiol The therapeutic efficacy of Luprostiol can be decreased when used in combination with Ketoprofen. Vet Approved Magnesium salicylate The risk or severity of adverse effects can be increased when Ketoprofen is combined with Magnesium salicylate. Approved Manidipine The therapeutic efficacy of Manidipine can be decreased when used in combination with Ketoprofen. Approved, Investigational Masoprocol The risk or severity of adverse effects can be increased when Masoprocol is combined with Ketoprofen. Approved, Investigational ME-609 The risk or severity of adverse effects can be increased when Ketoprofen is combined with ME-609. Investigational Meclofenamic acid The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Ketoprofen. Approved, Vet Approved Medrysone The risk or severity of adverse effects can be increased when Ketoprofen is combined with Medrysone. Approved Mefenamic acid The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Ketoprofen. Approved Melagatran Ketoprofen may increase the anticoagulant activities of Melagatran. Experimental Melengestrol The risk or severity of adverse effects can be increased when Ketoprofen is combined with Melengestrol. Vet Approved Meloxicam The risk or severity of adverse effects can be increased when Meloxicam is combined with Ketoprofen. Approved, Vet Approved Mepindolol Ketoprofen may decrease the antihypertensive activities of Mepindolol. Experimental Mesalazine The risk or severity of adverse effects can be increased when Mesalazine is combined with Ketoprofen. Approved Mestranol Ketoprofen may increase the thrombogenic activities of Mestranol. Approved Metamizole The risk or severity of adverse effects can be increased when Metamizole is combined with Ketoprofen. Approved, Investigational, Withdrawn Methallenestril Ketoprofen may increase the thrombogenic activities of Methallenestril. Experimental Methotrexate The serum concentration of Methotrexate can be increased when it is combined with Ketoprofen. Approved Methyclothiazide The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Ketoprofen. Approved Methyl salicylate The therapeutic efficacy of Methyl salicylate can be decreased when used in combination with Ketoprofen. Approved, Vet Approved Methylprednisolone The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Ketoprofen. Approved, Vet Approved Metipranolol Ketoprofen may decrease the antihypertensive activities of Metipranolol. Approved Metolazone The therapeutic efficacy of Metolazone can be decreased when used in combination with Ketoprofen. Approved Metoprolol Ketoprofen may decrease the antihypertensive activities of Metoprolol. Approved, Investigational Mibefradil The therapeutic efficacy of Mibefradil can be decreased when used in combination with Ketoprofen. Investigational, Withdrawn Micronomicin Ketoprofen may decrease the excretion rate of Micronomicin which could result in a higher serum level. Experimental Midostaurin The metabolism of Ketoprofen can be decreased when combined with Midostaurin. Approved, Investigational Mifamurtide The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Ketoprofen. Approved, Experimental Mifepristone The serum concentration of Ketoprofen can be increased when it is combined with Mifepristone. Approved, Investigational Milnacipran Milnacipran may increase the antiplatelet activities of Ketoprofen. Approved, Investigational Minoxidil The therapeutic efficacy of Minoxidil can be decreased when used in combination with Ketoprofen. Approved, Investigational Misoprostol The therapeutic efficacy of Misoprostol can be decreased when used in combination with Ketoprofen. Approved Mizoribine The risk or severity of adverse effects can be increased when Mizoribine is combined with Ketoprofen. Investigational Moexipril The risk or severity of adverse effects can be increased when Ketoprofen is combined with Moexipril. Approved Mofebutazone The risk or severity of adverse effects can be increased when Mofebutazone is combined with Ketoprofen. Experimental Mometasone The risk or severity of adverse effects can be increased when Ketoprofen is combined with Mometasone. Approved, Vet Approved Morniflumate The risk or severity of adverse effects can be increased when Morniflumate is combined with Ketoprofen. Approved Moxestrol Ketoprofen may increase the thrombogenic activities of Moxestrol. Experimental Moxifloxacin Ketoprofen may increase the neuroexcitatory activities of Moxifloxacin. Approved, Investigational Mycophenolate mofetil The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Ketoprofen. Approved, Investigational Mycophenolic acid The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Ketoprofen. Approved Nabilone The metabolism of Ketoprofen can be decreased when combined with Nabilone. Approved, Investigational Nabumetone The risk or severity of adverse effects can be increased when Nabumetone is combined with Ketoprofen. Approved Nadolol Ketoprofen may decrease the antihypertensive activities of Nadolol. Approved Nadroparin Ketoprofen may increase the anticoagulant activities of Nadroparin. Approved, Investigational Nafamostat The risk or severity of adverse effects can be increased when Nafamostat is combined with Ketoprofen. Approved, Investigational Naftifine The risk or severity of adverse effects can be increased when Naftifine is combined with Ketoprofen. Approved Naftopidil The therapeutic efficacy of Naftopidil can be decreased when used in combination with Ketoprofen. Investigational Nalidixic Acid Ketoprofen may increase the neuroexcitatory activities of Nalidixic Acid. Approved, Investigational Naproxen The risk or severity of adverse effects can be increased when Naproxen is combined with Ketoprofen. Approved, Vet Approved NCX 1022 The risk or severity of adverse effects can be increased when Ketoprofen is combined with NCX 1022. Investigational Neamine Ketoprofen may decrease the excretion rate of Neamine which could result in a higher serum level. Experimental Nebivolol Ketoprofen may decrease the antihypertensive activities of Nebivolol. Approved, Investigational Nefazodone Nefazodone may increase the antiplatelet activities of Ketoprofen. Approved, Withdrawn Nemonoxacin Ketoprofen may increase the neuroexcitatory activities of Nemonoxacin. Investigational Neomycin The risk or severity of nephrotoxicity can be increased when Ketoprofen is combined with Neomycin. Approved, Vet Approved Nepafenac The risk or severity of adverse effects can be increased when Nepafenac is combined with Ketoprofen. Approved, Investigational Netilmicin Ketoprofen may decrease the excretion rate of Netilmicin which could result in a higher serum level. Approved, Investigational Nicardipine The therapeutic efficacy of Nicardipine can be decreased when used in combination with Ketoprofen. Approved, Investigational Nifenazone The risk or severity of adverse effects can be increased when Nifenazone is combined with Ketoprofen. Experimental Niflumic Acid The risk or severity of adverse effects can be increased when Ketoprofen is combined with Niflumic Acid. Approved Niguldipine The therapeutic efficacy of Niguldipine can be decreased when used in combination with Ketoprofen. Experimental Nilvadipine The therapeutic efficacy of Nilvadipine can be decreased when used in combination with Ketoprofen. Approved, Investigational Nimesulide The risk or severity of adverse effects can be increased when Ketoprofen is combined with Nimesulide. Approved, Investigational, Withdrawn Nimodipine The therapeutic efficacy of Nimodipine can be decreased when used in combination with Ketoprofen. Approved, Investigational Nisoldipine The therapeutic efficacy of Nisoldipine can be decreased when used in combination with Ketoprofen. Approved Nitrendipine The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Ketoprofen. Approved, Investigational Nitroaspirin The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Ketoprofen. Investigational Norfloxacin Ketoprofen may increase the neuroexcitatory activities of Norfloxacin. Approved Ofloxacin Ketoprofen may increase the neuroexcitatory activities of Ofloxacin. Approved Oleoyl-estrone The risk or severity of adverse effects can be increased when Ketoprofen is combined with Oleoyl-estrone. Investigational Olmesartan The risk or severity of adverse effects can be increased when Olmesartan is combined with Ketoprofen. Approved, Investigational Olopatadine The risk or severity of adverse effects can be increased when Olopatadine is combined with Ketoprofen. Approved Olsalazine The risk or severity of adverse effects can be increased when Olsalazine is combined with Ketoprofen. Approved Omacetaxine mepesuccinate The risk or severity of bleeding can be increased when Ketoprofen is combined with Omacetaxine mepesuccinate. Approved, Investigational Omapatrilat The risk or severity of adverse effects can be increased when Ketoprofen is combined with Omapatrilat. Investigational Orgotein The risk or severity of adverse effects can be increased when Orgotein is combined with Ketoprofen. Vet Approved Otamixaban Ketoprofen may increase the anticoagulant activities of Otamixaban. Investigational Oxaprozin The risk or severity of adverse effects can be increased when Oxaprozin is combined with Ketoprofen. Approved Oxolinic acid Ketoprofen may increase the neuroexcitatory activities of Oxolinic acid. Experimental Oxprenolol Ketoprofen may decrease the antihypertensive activities of Oxprenolol. Approved Oxyphenbutazone The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Ketoprofen. Approved, Withdrawn Palmidrol The risk or severity of adverse effects can be increased when Palmidrol is combined with Ketoprofen. Experimental, Nutraceutical Pamidronate The risk or severity of adverse effects can be increased when Ketoprofen is combined with Pamidronate. Approved Paramethasone The risk or severity of adverse effects can be increased when Ketoprofen is combined with Paramethasone. Approved Parecoxib The risk or severity of adverse effects can be increased when Ketoprofen is combined with Parecoxib. Approved Paromomycin The risk or severity of nephrotoxicity can be increased when Ketoprofen is combined with Paromomycin. Approved, Investigational Paroxetine Paroxetine may increase the antiplatelet activities of Ketoprofen. Approved, Investigational Parthenolide The risk or severity of adverse effects can be increased when Parthenolide is combined with Ketoprofen. Approved, Investigational Pazufloxacin Ketoprofen may increase the neuroexcitatory activities of Pazufloxacin. Investigational Pefloxacin Ketoprofen may increase the neuroexcitatory activities of Pefloxacin. Approved Penbutolol Ketoprofen may decrease the antihypertensive activities of Penbutolol. Approved, Investigational Pentaerythritol Tetranitrate Ketoprofen may increase the anticoagulant activities of Pentaerythritol Tetranitrate. Approved Pentosan Polysulfate Ketoprofen may increase the anticoagulant activities of Pentosan Polysulfate. Approved Perindopril The risk or severity of adverse effects can be increased when Ketoprofen is combined with Perindopril. Approved Phenindione Ketoprofen may increase the anticoagulant activities of Phenindione. Approved, Investigational Phenobarbital The serum concentration of Ketoprofen can be decreased when it is combined with Phenobarbital. Approved, Investigational Phenprocoumon Ketoprofen may increase the anticoagulant activities of Phenprocoumon. Approved, Investigational Phenylbutazone The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Ketoprofen. Approved, Vet Approved Phenytoin The metabolism of Ketoprofen can be increased when combined with Phenytoin. Approved, Vet Approved Pimecrolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ketoprofen. Approved, Investigational Pindolol Ketoprofen may decrease the antihypertensive activities of Pindolol. Approved, Investigational Pipemidic acid Ketoprofen may increase the neuroexcitatory activities of Pipemidic acid. Experimental Piretanide The therapeutic efficacy of Piretanide can be decreased when used in combination with Ketoprofen. Approved Pirfenidone The risk or severity of adverse effects can be increased when Pirfenidone is combined with Ketoprofen. Approved, Investigational Piromidic acid Ketoprofen may increase the neuroexcitatory activities of Piromidic acid. Experimental Piroxicam The risk or severity of adverse effects can be increased when Piroxicam is combined with Ketoprofen. Approved, Investigational Pirprofen The risk or severity of adverse effects can be increased when Pirprofen is combined with Ketoprofen. Experimental Pitolisant The risk or severity of adverse effects can be increased when Ketoprofen is combined with Pitolisant. Approved, Investigational Platelet Activating Factor Ketoprofen may decrease the antihypertensive activities of Platelet Activating Factor. Experimental Plazomicin Ketoprofen may decrease the excretion rate of Plazomicin which could result in a higher serum level. Approved, Investigational Polyestradiol phosphate Ketoprofen may increase the thrombogenic activities of Polyestradiol phosphate. Approved Polythiazide The therapeutic efficacy of Polythiazide can be decreased when used in combination with Ketoprofen. Approved Pomalidomide The risk or severity of adverse effects can be increased when Ketoprofen is combined with Pomalidomide. Approved Potassium Citrate Ketoprofen may increase the anticoagulant activities of Potassium Citrate. Approved, Investigational, Vet Approved Practolol Ketoprofen may decrease the antihypertensive activities of Practolol. Approved Pralatrexate The serum concentration of Pralatrexate can be increased when it is combined with Ketoprofen. Approved, Investigational Pranoprofen The risk or severity of adverse effects can be increased when Pranoprofen is combined with Ketoprofen. Experimental, Investigational Prasterone The risk or severity of adverse effects can be increased when Ketoprofen is combined with Prasterone. Approved, Investigational, Nutraceutical Prasterone sulfate The risk or severity of adverse effects can be increased when Ketoprofen is combined with Prasterone sulfate. Investigational Prednicarbate The risk or severity of adverse effects can be increased when Ketoprofen is combined with Prednicarbate. Approved, Investigational Prednisolone The risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Ketoprofen. Approved, Vet Approved Prednisone The risk or severity of adverse effects can be increased when Ketoprofen is combined with Prednisone. Approved, Vet Approved Pregnenolone The risk or severity of adverse effects can be increased when Ketoprofen is combined with Pregnenolone. Approved, Experimental, Investigational Primidone The metabolism of Ketoprofen can be increased when combined with Primidone. Approved, Vet Approved Probenecid The serum concentration of Ketoprofen can be increased when it is combined with Probenecid. Approved, Investigational Proglumetacin The risk or severity of adverse effects can be increased when Proglumetacin is combined with Ketoprofen. Experimental Promestriene Ketoprofen may increase the thrombogenic activities of Promestriene. Investigational Propacetamol The risk or severity of adverse effects can be increased when Propacetamol is combined with Ketoprofen. Approved, Investigational Propafenone Ketoprofen may decrease the antihypertensive activities of Propafenone. Approved Propranolol Ketoprofen may decrease the antihypertensive activities of Propranolol. Approved, Investigational Propyphenazone The risk or severity of adverse effects can be increased when Propyphenazone is combined with Ketoprofen. Experimental Proquazone The risk or severity of adverse effects can be increased when Proquazone is combined with Ketoprofen. Experimental Prostaglandin B2 The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Ketoprofen. Experimental Prostaglandin G2 The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Ketoprofen. Experimental Prostalene The therapeutic efficacy of Prostalene can be decreased when used in combination with Ketoprofen. Vet Approved Protein C Ketoprofen may increase the anticoagulant activities of Protein C. Approved Protein S human Ketoprofen may increase the anticoagulant activities of Protein S human. Approved Protocatechualdehyde Ketoprofen may increase the anticoagulant activities of Protocatechualdehyde. Approved Prulifloxacin Ketoprofen may increase the neuroexcitatory activities of Prulifloxacin. Investigational PTC299 The risk or severity of adverse effects can be increased when PTC299 is combined with Ketoprofen. Investigational Puromycin Ketoprofen may decrease the excretion rate of Puromycin which could result in a higher serum level. Experimental Pyrimethamine The metabolism of Ketoprofen can be decreased when combined with Pyrimethamine. Approved, Investigational, Vet Approved Quinapril The risk or severity of adverse effects can be increased when Ketoprofen is combined with Quinapril. Approved, Investigational Quinestrol Ketoprofen may increase the thrombogenic activities of Quinestrol. Approved Quinethazone The therapeutic efficacy of Quinethazone can be decreased when used in combination with Ketoprofen. Approved Quinine The metabolism of Ketoprofen can be decreased when combined with Quinine. Approved Ramipril The risk or severity of adverse effects can be increased when Ketoprofen is combined with Ramipril. Approved Rescinnamine The risk or severity of adverse effects can be increased when Ketoprofen is combined with Rescinnamine. Approved Resveratrol The risk or severity of adverse effects can be increased when Ketoprofen is combined with Resveratrol. Approved, Experimental, Investigational Reviparin Ketoprofen may increase the anticoagulant activities of Reviparin. Approved, Investigational Ribostamycin Ketoprofen may decrease the excretion rate of Ribostamycin which could result in a higher serum level. Approved, Investigational Rifampicin The serum concentration of Ketoprofen can be decreased when it is combined with Rifampicin. Approved Rifapentine The metabolism of Ketoprofen can be increased when combined with Rifapentine. Approved, Investigational Rimexolone The risk or severity of adverse effects can be increased when Ketoprofen is combined with Rimexolone. Approved Risedronate The risk or severity of adverse effects can be increased when Ketoprofen is combined with Risedronate. Approved, Investigational Rivaroxaban Ketoprofen may increase the anticoagulant activities of Rivaroxaban. Approved Rofecoxib The risk or severity of adverse effects can be increased when Rofecoxib is combined with Ketoprofen. Approved, Investigational, Withdrawn Rosoxacin Ketoprofen may increase the neuroexcitatory activities of Rosoxacin. Approved, Investigational Rucaparib The metabolism of Ketoprofen can be decreased when combined with Rucaparib. Approved, Investigational Rufloxacin Ketoprofen may increase the neuroexcitatory activities of Rufloxacin. Experimental Sacubitril The risk or severity of adverse effects can be increased when Sacubitril is combined with Ketoprofen. Approved Salicylamide The risk or severity of adverse effects can be increased when Salicylamide is combined with Ketoprofen. Approved Salicylic acid The risk or severity of adverse effects can be increased when Salicylic acid is combined with Ketoprofen. Approved, Investigational, Vet Approved Salsalate The risk or severity of adverse effects can be increased when Ketoprofen is combined with Salsalate. Approved Saprisartan The risk or severity of adverse effects can be increased when Saprisartan is combined with Ketoprofen. Experimental Saralasin The risk or severity of adverse effects can be increased when Saralasin is combined with Ketoprofen. Investigational Sarilumab Sarilumab may increase the immunosuppressive activities of Ketoprofen. Approved, Investigational Secobarbital The metabolism of Ketoprofen can be increased when combined with Secobarbital. Approved, Vet Approved Secoisolariciresinol Ketoprofen may increase the thrombogenic activities of Secoisolariciresinol. Investigational Seliciclib The risk or severity of adverse effects can be increased when Ketoprofen is combined with Seliciclib. Investigational Semapimod The risk or severity of adverse effects can be increased when Semapimod is combined with Ketoprofen. Investigational Seratrodast The risk or severity of adverse effects can be increased when Seratrodast is combined with Ketoprofen. Approved Serrapeptase The risk or severity of adverse effects can be increased when Serrapeptase is combined with Ketoprofen. Investigational Sertraline Sertraline may increase the antiplatelet activities of Ketoprofen. Approved Sildenafil The metabolism of Ketoprofen can be decreased when combined with Sildenafil. Approved, Investigational Sisomicin Ketoprofen may decrease the excretion rate of Sisomicin which could result in a higher serum level. Investigational Sitafloxacin Ketoprofen may increase the neuroexcitatory activities of Sitafloxacin. Experimental, Investigational Sodium Citrate The risk or severity of bleeding and hemorrhage can be increased when Ketoprofen is combined with Sodium Citrate. Approved, Investigational Sodium phosphate, monobasic The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Ketoprofen. Approved Sorafenib The metabolism of Ketoprofen can be decreased when combined with Sorafenib. Approved, Investigational Sotalol Ketoprofen may decrease the antihypertensive activities of Sotalol. Approved Sparfloxacin Ketoprofen may increase the neuroexcitatory activities of Sparfloxacin. Approved, Investigational Spirapril The risk or severity of adverse effects can be increased when Ketoprofen is combined with Spirapril. Approved Spironolactone The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ketoprofen is combined with Spironolactone. Approved SRT501 The risk or severity of adverse effects can be increased when SRT501 is combined with Ketoprofen. Investigational Streptomycin Ketoprofen may decrease the excretion rate of Streptomycin which could result in a higher serum level. Approved, Vet Approved Sulfadiazine The metabolism of Ketoprofen can be decreased when combined with Sulfadiazine. Approved, Investigational, Vet Approved Sulfamethoxazole The metabolism of Ketoprofen can be decreased when combined with Sulfamethoxazole. Approved Sulfasalazine The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Ketoprofen. Approved Sulfisoxazole The metabolism of Ketoprofen can be decreased when combined with Sulfisoxazole. Approved, Vet Approved Sulindac The risk or severity of adverse effects can be increased when Sulindac is combined with Ketoprofen. Approved, Investigational Sulodexide Ketoprofen may increase the anticoagulant activities of Sulodexide. Approved, Investigational Sulprostone The therapeutic efficacy of Sulprostone can be decreased when used in combination with Ketoprofen. Investigational Suprofen The risk or severity of adverse effects can be increased when Suprofen is combined with Ketoprofen. Approved, Withdrawn Suxibuzone The risk or severity of adverse effects can be increased when Suxibuzone is combined with Ketoprofen. Experimental Synthetic Conjugated Estrogens, A Ketoprofen may increase the thrombogenic activities of Synthetic Conjugated Estrogens, A. Approved Synthetic Conjugated Estrogens, B Ketoprofen may increase the thrombogenic activities of Synthetic Conjugated Estrogens, B. Approved Tacrolimus Ketoprofen may increase the nephrotoxic activities of Tacrolimus. Approved, Investigational Tafluprost The therapeutic efficacy of Tafluprost can be decreased when used in combination with Ketoprofen. Approved Talinolol Ketoprofen may decrease the antihypertensive activities of Talinolol. Investigational Talniflumate The risk or severity of adverse effects can be increased when Talniflumate is combined with Ketoprofen. Approved Tarenflurbil The risk or severity of adverse effects can be increased when Tarenflurbil is combined with Ketoprofen. Investigational Tasosartan The risk or severity of adverse effects can be increased when Tasosartan is combined with Ketoprofen. Approved Technetium Tc-99m etidronate The risk or severity of adverse effects can be increased when Ketoprofen is combined with Technetium Tc-99m etidronate. Approved Technetium Tc-99m medronate The risk or severity of adverse effects can be increased when Ketoprofen is combined with Technetium Tc-99m medronate. Approved Telmisartan The risk or severity of adverse effects can be increased when Telmisartan is combined with Ketoprofen. Approved, Investigational Temafloxacin Ketoprofen may increase the neuroexcitatory activities of Temafloxacin. Withdrawn Temocapril The risk or severity of adverse effects can be increased when Ketoprofen is combined with Temocapril. Experimental, Investigational Tenidap The risk or severity of adverse effects can be increased when Tenidap is combined with Ketoprofen. Experimental Tenofovir disoproxil The risk or severity of adverse effects can be increased when Ketoprofen is combined with Tenofovir disoproxil. Approved, Investigational Tenoxicam The risk or severity of adverse effects can be increased when Tenoxicam is combined with Ketoprofen. Approved Tepoxalin The risk or severity of adverse effects can be increased when Tepoxalin is combined with Ketoprofen. Vet Approved Terbutaline Ketoprofen may decrease the antihypertensive activities of Terbutaline. Approved Teriflunomide The risk or severity of adverse effects can be increased when Teriflunomide is combined with Ketoprofen. Approved Tertatolol Ketoprofen may decrease the antihypertensive activities of Tertatolol. Experimental Tetracycline The excretion of Tetracycline can be decreased when combined with Ketoprofen. Approved, Vet Approved Tetrahydropalmatine The therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Ketoprofen. Investigational Tiaprofenic acid The risk or severity of adverse effects can be increased when Ketoprofen is combined with Tiaprofenic acid. Approved Tibolone Ketoprofen may increase the thrombogenic activities of Tibolone. Approved, Investigational Ticagrelor The metabolism of Ketoprofen can be decreased when combined with Ticagrelor. Approved Ticlopidine The metabolism of Ketoprofen can be decreased when combined with Ticlopidine. Approved Tiludronic acid The risk or severity of adverse effects can be increased when Ketoprofen is combined with Tiludronic acid. Approved, Investigational, Vet Approved Timolol Ketoprofen may decrease the antihypertensive activities of Timolol. Approved Tinoridine The risk or severity of adverse effects can be increased when Tinoridine is combined with Ketoprofen. Investigational Tioclomarol Ketoprofen may increase the anticoagulant activities of Tioclomarol. Experimental Tixocortol The risk or severity of adverse effects can be increased when Ketoprofen is combined with Tixocortol. Approved, Withdrawn Tobramycin Ketoprofen may decrease the excretion rate of Tobramycin which could result in a higher serum level. Approved, Investigational Tolbutamide The metabolism of Ketoprofen can be decreased when combined with Tolbutamide. Approved, Investigational Tolfenamic Acid The risk or severity of adverse effects can be increased when Ketoprofen is combined with Tolfenamic Acid. Approved, Investigational Tolmetin The risk or severity of adverse effects can be increased when Tolmetin is combined with Ketoprofen. Approved Topiroxostat The metabolism of Ketoprofen can be decreased when combined with Topiroxostat. Approved, Investigational Torasemide The therapeutic efficacy of Torasemide can be decreased when used in combination with Ketoprofen. Approved Trandolapril The risk or severity of adverse effects can be increased when Ketoprofen is combined with Trandolapril. Approved Travoprost The therapeutic efficacy of Travoprost can be decreased when used in combination with Ketoprofen. Approved Treprostinil The risk or severity of adverse effects can be increased when Treprostinil is combined with Ketoprofen. Approved, Investigational Triamcinolone The risk or severity of adverse effects can be increased when Ketoprofen is combined with Triamcinolone. Approved, Vet Approved Triamterene Ketoprofen may decrease the antihypertensive activities of Triamterene. Approved Tribenoside The risk or severity of adverse effects can be increased when Tribenoside is combined with Ketoprofen. Experimental Trichlormethiazide The therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Ketoprofen. Approved, Vet Approved Trimethoprim The metabolism of Ketoprofen can be decreased when combined with Trimethoprim. Approved, Vet Approved Triptolide The risk or severity of adverse effects can be increased when Triptolide is combined with Ketoprofen. Investigational Trolamine salicylate The risk or severity of adverse effects can be increased when Ketoprofen is combined with Trolamine salicylate. Approved Trovafloxacin Ketoprofen may increase the neuroexcitatory activities of Trovafloxacin. Approved, Investigational, Withdrawn Troxerutin Ketoprofen may increase the anticoagulant activities of Troxerutin. Investigational Ulobetasol The risk or severity of adverse effects can be increased when Ketoprofen is combined with Ulobetasol. Approved Unoprostone The therapeutic efficacy of Unoprostone can be decreased when used in combination with Ketoprofen. Approved, Investigational Valdecoxib The risk or severity of adverse effects can be increased when Valdecoxib is combined with Ketoprofen. Approved, Investigational, Withdrawn Valsartan The metabolism of Ketoprofen can be decreased when combined with Valsartan. Approved, Investigational Vancomycin Ketoprofen may decrease the excretion rate of Vancomycin which could result in a higher serum level. Approved Venlafaxine Venlafaxine may increase the antiplatelet activities of Ketoprofen. Approved Voriconazole The metabolism of Ketoprofen can be decreased when combined with Voriconazole. Approved, Investigational Warfarin Ketoprofen may increase the anticoagulant activities of Warfarin. Approved Ximelagatran Ketoprofen may increase the anticoagulant activities of Ximelagatran. Approved, Investigational, Withdrawn Zafirlukast The metabolism of Ketoprofen can be decreased when combined with Zafirlukast. Approved, Investigational Zaltoprofen The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Ketoprofen. Approved, Investigational Zeranol Ketoprofen may increase the thrombogenic activities of Zeranol. Vet Approved Zidovudine The serum concentration of Ketoprofen can be decreased when it is combined with Zidovudine. Approved Zileuton The risk or severity of adverse effects can be increased when Zileuton is combined with Ketoprofen. Approved, Investigational, Withdrawn Zimelidine Zimelidine may increase the antiplatelet activities of Ketoprofen. Withdrawn Zofenopril The risk or severity of adverse effects can be increased when Ketoprofen is combined with Zofenopril. Experimental Zoledronic acid The risk or severity of gastrointestinal bleeding can be increased when Ketoprofen is combined with Zoledronic acid. Approved Zomepirac The risk or severity of adverse effects can be increased when Zomepirac is combined with Ketoprofen. Withdrawn - Food Interactions
- Avoid alcohol.
- Food prolongs rate of absorption and decreases peak plasma concentration. Extent of absorption is not affected.
- Take with food to reduce gastric irritation.
References
- Synthesis Reference
Attilio Citterio, Daniele Fancelli, "Method of preparing ketoprofen." U.S. Patent US4845281, issued December, 1982.
US4845281- General References
- Kantor TG: Ketoprofen: a review of its pharmacologic and clinical properties. Pharmacotherapy. 1986 May-Jun;6(3):93-103. [PubMed:3526298]
- Mazieres B: Topical ketoprofen patch. Drugs R D. 2005;6(6):337-44. [PubMed:16274258]
- External Links
- Human Metabolome Database
- HMDB0015144
- KEGG Drug
- D00132
- KEGG Compound
- C01716
- PubChem Compound
- 3825
- PubChem Substance
- 46505715
- ChemSpider
- 3693
- BindingDB
- 50022271
- ChEBI
- 6128
- ChEMBL
- CHEMBL571
- Therapeutic Targets Database
- DAP000623
- PharmGKB
- PA450149
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- PDRhealth
- PDRhealth Drug Page
- Wikipedia
- Ketoprofen
- ATC Codes
- M01AE53 — Ketoprofen, combinations
- M01AE — Propionic acid derivatives
- M01A — ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
- M01 — ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
- M — MUSCULO-SKELETAL SYSTEM
- M02AA — Antiinflammatory preparations, non-steroids for topical use
- M02A — TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN
- M02 — TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN
- M — MUSCULO-SKELETAL SYSTEM
- AHFS Codes
- 28:08.04.92 — Other Nonsteroidal Antiimflammatory Agents
- FDA label
- Download (160 KB)
- MSDS
- Download (75.9 KB)
Clinical Trials
- Clinical Trials
Pharmacoeconomics
- Manufacturers
- Elan pharmaceutical research corp
- Mylan pharmaceuticals inc
- Watson laboratories inc florida
- Wyeth pharmaceuticals inc
- Heritage pharmaceuticals inc
- Sandoz inc
- Teva pharmaceuticals usa inc
- Wyeth ayerst laboratories
- Novartis consumer health inc
- Bayer healthcare llc
- L perrigo co
- Wyeth consumer healthcare
- Packagers
- Aidarex Pharmacuticals LLC
- Apothecary Shop Wholesale
- A-S Medication Solutions LLC
- Bryant Ranch Prepack
- Corepharma LLC
- Direct Dispensing Inc.
- Dispensing Solutions
- Diversified Healthcare Services Inc.
- Elan Pharmaceuticals Inc.
- H.J. Harkins Co. Inc.
- Innoviant Pharmacy Inc.
- Letco Medical Inc.
- Major Pharmaceuticals
- Medisca Inc.
- Murfreesboro Pharmaceutical Nursing Supply
- Mylan
- Nucare Pharmaceuticals Inc.
- Palmetto Pharmaceuticals Inc.
- PD-Rx Pharmaceuticals Inc.
- Pharma Pac LLC
- Pharmedix
- Physicians Total Care Inc.
- Preferred Pharmaceuticals Inc.
- Prescription Dispensing Service Inc.
- Professional Co.
- Qualitest
- Rebel Distributors Corp.
- Sandhills Packaging Inc.
- Southwood Pharmaceuticals
- Teva Pharmaceutical Industries Ltd.
- Watson Pharmaceuticals
- Dosage forms
Form Route Strength Capsule Oral 25 mg/1 Capsule Oral 50 mg Capsule Oral 50 mg/1 Capsule Oral 75 mg/1 Capsule, extended release Oral 200 mg/1 Tablet Oral 75 mg/1 Tablet, extended release Oral 200 mg Tablet, delayed release Oral 100 mg Tablet, delayed release Oral 50 mg Suppository Rectal 50 mg Capsule, extended release Oral 150 mg Capsule, extended release Oral 200 mg Suppository Rectal 100 mg Kit - Prices
Unit description Cost Unit Ketoprofen powder 43.74USD g Ketoprofen micronized powder 3.84USD g Ketoprofen CR 200 mg 24 Hour Capsule 2.8USD capsule Orudis 75 mg capsule 1.58USD capsule Apo-Keto Sr 200 mg Sustained-Release Tablet 1.46USD tablet Ketoprofen 75 mg capsule 1.12USD capsule Pms-Ketoprofen 100 mg Suppository 1.1USD suppository Ketoprofen 50 mg capsule 1.0USD capsule Apo-Keto-E 100 mg Enteric-Coated Tablet 0.71USD tablet Apo-Keto 50 mg Capsule 0.35USD capsule Apo-Keto-E 50 mg Enteric-Coated Tablet 0.35USD tablet Orudis kt 12.5 mg tablet 0.3USD tablet DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 94 °C U.S. Patent 3,641,127. water solubility 51 mg/L (at 22 °C) YALKOWSKY,SH & DANNENFELSER,RM (1992) logP 3.12 SANGSTER (1993) logS -3.7 ADME Research, USCD pKa 4.45 SANGSTER (1994) - Predicted Properties
Property Value Source Water Solubility 0.0213 mg/mL ALOGPS logP 3.29 ALOGPS logP 3.61 ChemAxon logS -4.1 ALOGPS pKa (Strongest Acidic) 3.88 ChemAxon pKa (Strongest Basic) -7.5 ChemAxon Physiological Charge -1 ChemAxon Hydrogen Acceptor Count 3 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 54.37 Å2 ChemAxon Rotatable Bond Count 4 ChemAxon Refractivity 72.52 m3·mol-1 ChemAxon Polarizability 26.56 Å3 ChemAxon Number of Rings 2 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.9928 Blood Brain Barrier + 0.9382 Caco-2 permeable + 0.8866 P-glycoprotein substrate Non-substrate 0.7132 P-glycoprotein inhibitor I Non-inhibitor 0.9168 P-glycoprotein inhibitor II Non-inhibitor 0.9589 Renal organic cation transporter Non-inhibitor 0.8818 CYP450 2C9 substrate Non-substrate 0.7183 CYP450 2D6 substrate Non-substrate 0.9598 CYP450 3A4 substrate Non-substrate 0.7685 CYP450 1A2 substrate Non-inhibitor 0.9046 CYP450 2C9 inhibitor Non-inhibitor 0.907 CYP450 2D6 inhibitor Non-inhibitor 0.9604 CYP450 2C19 inhibitor Non-inhibitor 0.9465 CYP450 3A4 inhibitor Non-inhibitor 0.9598 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9438 Ames test Non AMES toxic 0.9801 Carcinogenicity Non-carcinogens 0.6299 Biodegradation Ready biodegradable 0.6701 Rat acute toxicity 2.2378 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9661 hERG inhibition (predictor II) Non-inhibitor 0.9595
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as benzophenones. These are organic compounds containing a ketone attached to two phenyl groups.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Benzophenones
- Direct Parent
- Benzophenones
- Alternative Parents
- Diphenylmethanes / Aryl-phenylketones / Phenylpropanoic acids / Benzoyl derivatives / Monocarboxylic acids and derivatives / Carboxylic acids / Organic oxides / Hydrocarbon derivatives
- Substituents
- Benzophenone / Aryl-phenylketone / Diphenylmethane / 2-phenylpropanoic-acid / Benzoyl / Aryl ketone / Ketone / Carboxylic acid derivative / Carboxylic acid / Monocarboxylic acid or derivatives
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- benzophenones, oxo monocarboxylic acid (CHEBI:6128)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Prostaglandin-endoperoxide synthase activity
- Specific Function
- Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
- Gene Name
- PTGS1
- Uniprot ID
- P23219
- Uniprot Name
- Prostaglandin G/H synthase 1
- Molecular Weight
- 68685.82 Da
References
- Parsadaniantz SM, Lebeau A, Duval P, Grimaldi B, Terlain B, Kerdelhue B: Effects of the inhibition of cyclo-oxygenase 1 or 2 or 5-lipoxygenase on the activation of the hypothalamic-pituitary-adrenal axis induced by interleukin-1beta in the male Rat. J Neuroendocrinol. 2000 Aug;12(8):766-73. [PubMed:10929089]
- Kurahashi K, Shirahase H, Nakamura S, Tarumi T, Koshino Y, Wang AM, Nishihashi T, Shimizu Y: Nicotine-induced contraction in the rat coronary artery: possible involvement of the endothelium, reactive oxygen species and COX-1 metabolites. J Cardiovasc Pharmacol. 2001 Oct;38 Suppl 1:S21-5. [PubMed:11811354]
- Zuniga J, Fuenzalida M, Guerrero A, Illanes J, Dabancens A, Diaz E, Lemus D: Effects of steroidal and non steroidal drugs on the neovascularization response induced by tumoral TA3 supernatant on CAM from chick embryo. Biol Res. 2003;36(2):233-40. [PubMed:14513718]
- Martic M, Tatic I, Markovic S, Kujundzic N, Kostrun S: Synthesis, biological activity and molecular modeling studies of novel COX-1 inhibitors. Eur J Med Chem. 2004 Feb;39(2):141-51. [PubMed:14987823]
- Levoin N, Blondeau C, Guillaume C, Grandcolas L, Chretien F, Jouzeau JY, Benoit E, Chapleur Y, Netter P, Lapicque F: Elucidation of the mechanism of inhibition of cyclooxygenases by acyl-coenzyme A and acylglucuronic conjugates of ketoprofen. Biochem Pharmacol. 2004 Nov 15;68(10):1957-69. [PubMed:15476667]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Prostaglandin-endoperoxide synthase activity
- Specific Function
- Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
- Gene Name
- PTGS2
- Uniprot ID
- P35354
- Uniprot Name
- Prostaglandin G/H synthase 2
- Molecular Weight
- 68995.625 Da
References
- Kay-Mugford P, Benn SJ, LaMarre J, Conlon P: In vitro effects of nonsteroidal anti-inflammatory drugs on cyclooxygenase activity in dogs. Am J Vet Res. 2000 Jul;61(7):802-10. [PubMed:10895904]
- Sommerauer M, Ates M, Guhring H, Brune K, Amann R, Peskar BA: Ketoprofen-induced cyclooxygenase inhibition in renal medulla and platelets of rats treated with caffeine. Pharmacology. 2001;63(4):234-9. [PubMed:11729362]
- Levoin N, Chretien F, Lapicque F, Chapleur Y: Synthesis and biological testing of Acyl-CoA-ketoprofen conjugates as selective irreversible inhibitors of COX-2. Bioorg Med Chem. 2002 Mar;10(3):753-7. [PubMed:11814865]
- Zuniga J, Fuenzalida M, Guerrero A, Illanes J, Dabancens A, Diaz E, Lemus D: Effects of steroidal and non steroidal drugs on the neovascularization response induced by tumoral TA3 supernatant on CAM from chick embryo. Biol Res. 2003;36(2):233-40. [PubMed:14513718]
- Wilson JE, Chandrasekharan NV, Westover KD, Eager KB, Simmons DL: Determination of expression of cyclooxygenase-1 and -2 isozymes in canine tissues and their differential sensitivity to nonsteroidal anti-inflammatory drugs. Am J Vet Res. 2004 Jun;65(6):810-8. [PubMed:15198222]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Other
- General Function
- Interleukin-8 receptor activity
- Specific Function
- Receptor to interleukin-8, which is a powerful neutrophils chemotactic factor. Binding of IL-8 to the receptor causes activation of neutrophils. This response is mediated via a G-protein that activ...
- Gene Name
- CXCR1
- Uniprot ID
- P25024
- Uniprot Name
- C-X-C chemokine receptor type 1
- Molecular Weight
- 39790.735 Da
References
- Allegretti M, Bertini R, Cesta MC, Bizzarri C, Di Bitondo R, Di Cioccio V, Galliera E, Berdini V, Topai A, Zampella G, Russo V, Di Bello N, Nano G, Nicolini L, Locati M, Fantucci P, Florio S, Colotta F: 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31. [PubMed:15974585]
- Bizzarri C, Pagliei S, Brandolini L, Mascagni P, Caselli G, Transidico P, Sozzani S, Bertini R: Selective inhibition of interleukin-8-induced neutrophil chemotaxis by ketoprofen isomers. Biochem Pharmacol. 2001 Jun 1;61(11):1429-37. [PubMed:11331079]
- Wang LM, Toyoshima A, Mineshita S, Wang XX, Yamamoto T, Nomura Y, Yang L, Koikei Y, Shiba K, Honda Y: The anti-inflammatory effects of ketoprofen in animal experiments. Drugs Exp Clin Res. 1997;23(1):1-6. [PubMed:9093816]
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitor
- General Function
- Steroid hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP2C9
- Uniprot ID
- P11712
- Uniprot Name
- Cytochrome P450 2C9
- Molecular Weight
- 55627.365 Da
References
- Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Steroid hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP2C8
- Uniprot ID
- P10632
- Uniprot Name
- Cytochrome P450 2C8
- Molecular Weight
- 55824.275 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- No
- Actions
- Substrate
- General Function
- Steroid binding
- Specific Function
- UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the...
- Gene Name
- UGT1A1
- Uniprot ID
- P22309
- Uniprot Name
- UDP-glucuronosyltransferase 1-1
- Molecular Weight
- 59590.91 Da
References
- Dancygier H. (2010). Clinical Hepatology. Springer-Verlag. [ISBN:978-3-642-04509-7]
Carriers
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Toxic substance binding
- Specific Function
- Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
- Gene Name
- ALB
- Uniprot ID
- P02768
- Uniprot Name
- Serum albumin
- Molecular Weight
- 69365.94 Da
References
- Bertucci C: Enantioselective inhibition of the binding of rac-profens to human serum albumin induced by lithocholate. Chirality. 2001 Jul;13(7):372-8. [PubMed:11400191]
- Lagrange F, Penhourcq F, Matoga M, Bannwarth B: Binding of ketoprofen enantiomers in various human albumin preparations. J Pharm Biomed Anal. 2000 Oct;23(5):793-802. [PubMed:11022905]
- Li F, Zhou D, Guo X: Study on the protein binding of ketoprofen using capillary electrophoresis frontal analysis compared with liquid chromatography frontal analysis. J Chromatogr Sci. 2003 Mar;41(3):137-41. [PubMed:12725696]
- Zhou D, Li F: [Study of protein binding in ketoprofen using liquid chromatography frontal analysis in comparison with capillary electrophoresis frontal analysis]. Se Pu. 2004 Nov;22(6):601-4. [PubMed:15807110]
Transporters
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Atpase activity, coupled to transmembrane movement of substances
- Specific Function
- May be an organic anion pump relevant to cellular detoxification.
- Gene Name
- ABCC4
- Uniprot ID
- O15439
- Uniprot Name
- Multidrug resistance-associated protein 4
- Molecular Weight
- 149525.33 Da
References
- Reid G, Wielinga P, Zelcer N, van der Heijden I, Kuil A, de Haas M, Wijnholds J, Borst P: The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9244-9. Epub 2003 Jun 30. [PubMed:12835412]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Sodium-independent organic anion transmembrane transporter activity
- Specific Function
- Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibit...
- Gene Name
- SLCO1A2
- Uniprot ID
- P46721
- Uniprot Name
- Solute carrier organic anion transporter family member 1A2
- Molecular Weight
- 74144.105 Da
References
- Shitara Y, Sugiyama D, Kusuhara H, Kato Y, Abe T, Meier PJ, Itoh T, Sugiyama Y: Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport. Pharm Res. 2002 Feb;19(2):147-53. [PubMed:11883641]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Sodium-independent organic anion transmembrane transporter activity
- Specific Function
- Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
- Gene Name
- SLC22A6
- Uniprot ID
- Q4U2R8
- Uniprot Name
- Solute carrier family 22 member 6
- Molecular Weight
- 61815.78 Da
References
- Cihlar T, Ho ES: Fluorescence-based assay for the interaction of small molecules with the human renal organic anion transporter 1. Anal Biochem. 2000 Jul 15;283(1):49-55. [PubMed:10929807]
- Mulato AS, Ho ES, Cihlar T: Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1. J Pharmacol Exp Ther. 2000 Oct;295(1):10-5. [PubMed:10991954]
- Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. [PubMed:12130730]
- Uwai Y, Saito H, Inui K: Interaction between methotrexate and nonsteroidal anti-inflammatory drugs in organic anion transporter. Eur J Pharmacol. 2000 Dec 1;409(1):31-6. [PubMed:11099697]
- Apiwattanakul N, Sekine T, Chairoungdua A, Kanai Y, Nakajima N, Sophasan S, Endou H: Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes. Mol Pharmacol. 1999 May;55(5):847-54. [PubMed:10220563]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Sodium-independent organic anion transmembrane transporter activity
- Specific Function
- Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenad...
- Gene Name
- SLC22A8
- Uniprot ID
- Q8TCC7
- Uniprot Name
- Solute carrier family 22 member 8
- Molecular Weight
- 59855.585 Da
References
- Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. [PubMed:12130730]
- Ohtsuki S, Asaba H, Takanaga H, Deguchi T, Hosoya K, Otagiri M, Terasaki T: Role of blood-brain barrier organic anion transporter 3 (OAT3) in the efflux of indoxyl sulfate, a uremic toxin: its involvement in neurotransmitter metabolite clearance from the brain. J Neurochem. 2002 Oct;83(1):57-66. [PubMed:12358729]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Sodium-independent organic anion transmembrane transporter activity
- Specific Function
- Mediates saturable uptake of estrone sulfate, dehydroepiandrosterone sulfate and related compounds.
- Gene Name
- SLC22A11
- Uniprot ID
- Q9NSA0
- Uniprot Name
- Solute carrier family 22 member 11
- Molecular Weight
- 59970.945 Da
References
- Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. [PubMed:12130730]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Sodium-independent organic anion transmembrane transporter activity
- Specific Function
- Mediates sodium-independent multispecific organic anion transport. Transport of prostaglandin E2, prostaglandin F2, tetracycline, bumetanide, estrone sulfate, glutarate, dehydroepiandrosterone sulf...
- Gene Name
- SLC22A7
- Uniprot ID
- Q9Y694
- Uniprot Name
- Solute carrier family 22 member 7
- Molecular Weight
- 60025.025 Da
References
- Sekine T, Cha SH, Tsuda M, Apiwattanakul N, Nakajima N, Kanai Y, Endou H: Identification of multispecific organic anion transporter 2 expressed predominantly in the liver. FEBS Lett. 1998 Jun 12;429(2):179-82. [PubMed:9650585]
- Morita N, Kusuhara H, Sekine T, Endou H, Sugiyama Y: Functional characterization of rat organic anion transporter 2 in LLC-PK1 cells. J Pharmacol Exp Ther. 2001 Sep;298(3):1179-84. [PubMed:11504818]
- Mulato AS, Ho ES, Cihlar T: Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1. J Pharmacol Exp Ther. 2000 Oct;295(1):10-5. [PubMed:10991954]
- Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. [PubMed:12130730]
Drug created on June 13, 2005 07:24 / Updated on August 15, 2018 09:47